GeneDx Holdings Corp (NASDAQ:WGS) Chief Financial Officer Kevin Feeley executed multiple sales of Class A Common Stock on March 26, 2026, disposing of 7,718 shares for roughly $557,051 in aggregate proceeds. Reported transaction prices ranged from $61.2909 to $65.2143 per share.
The stock had been under pressure in the days leading up to the trades, falling 17% over the prior week and trading at $59.55 at the time of the reporting.
On the same date as the sales, Feeley acquired 16,250 Class A shares by exercising restricted stock units, at a transaction price of $0. After accounting for these moves, Feeley directly owns 34,580 shares of GeneDx.
Market commentary from InvestingPro included an assessment that GeneDx appears undervalued at current prices and noted the company’s market valuation at $1.76 billion. The InvestingPro briefing also referenced 12 additional ProTips available to subscribers analyzing the equity.
GeneDx released fourth-quarter financial results showing revenue of $121.0 million, a 27% increase year-over-year. That top-line figure exceeded expectations, topping Canaccord Genuity’s estimate of $120.9 million and the consensus estimate of $120.4 million. Revenue from whole-exome sequencing and whole-genome sequencing (WES/WGS) rose 32% year-over-year to $104.0 million, a result the company said was in line with expectations.
Brokerage coverage following the quarterly update has remained constructive. BTIG lowered its price target to $170 from $200 while keeping a Buy rating after the company’s earnings call confirmed its 2026 guidance. Jefferies reiterated a Buy rating with a $150.00 price target, citing GeneDx’s data advantage presented at a recent conference. TD Cowen maintained a Buy rating and a $165.00 price target, highlighting expected growth in specialties such as geneticists and pediatric neurologists, and noting the company’s expectation of 25% to 27% growth from these sectors by 2026. Canaccord Genuity also reiterated its Buy rating and $170 price target, pointing to the firm’s strong financial performance.
Competitive developments noted in market commentary include Natera’s introduction of Zenith genomics, a new test for rare disease diagnosis, which could affect market dynamics for diagnostic testing.
Taken together, the insider transaction, the quarter’s financial outturn, and continued analyst support provide multiple data points for investors assessing GeneDx’s near-term outlook. The company’s reported revenue strength and analyst endorsements coexist with increased competition in the rare-disease testing market.